{
  "ticker": "BNTX",
  "company_name": "BioNTech SE",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04649021",
      "title": "Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "SARS-CoV-2",
      "start_date": "2020-12-04",
      "completion_date": "2022-01-09",
      "enrollment": 0,
      "sponsor": "BioNTech SE"
    },
    {
      "nct_id": "NCT03289962",
      "title": "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers",
      "start_date": "2017-12-21",
      "completion_date": "2025-07-01",
      "enrollment": 0,
      "sponsor": "Genentech, Inc."
    },
    {
      "nct_id": "NCT06046274",
      "title": "GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer",
      "status": "WITHDRAWN",
      "phase": "PHASE2",
      "condition": "Advanced Endometrial Cancer",
      "start_date": "2023-10-01",
      "completion_date": "2028-06-01",
      "enrollment": 0,
      "sponsor": "Genmab"
    },
    {
      "nct_id": "NCT02672917",
      "title": "Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies",
      "status": "TERMINATED",
      "phase": "PHASE1",
      "condition": "Pancreatic Cancer",
      "start_date": "2016-01",
      "completion_date": "2025-01-14",
      "enrollment": 0,
      "sponsor": "BioNTech Research & Development, Inc."
    },
    {
      "nct_id": "NCT02897765",
      "title": "A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Urinary Bladder Cancer, Bladder Tumors, Transitional Cell Carcinoma of the Bladder, Malignant Melanoma, Melanoma, Skin Cancer, Carcinoma, Non-Small-Cell Lung, Lung Cancer",
      "start_date": "2016-10",
      "completion_date": "2020-05",
      "enrollment": 0,
      "sponsor": "BioNTech US Inc."
    },
    {
      "nct_id": "NCT06449222",
      "title": "Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers",
      "start_date": "2024-08-26",
      "completion_date": "2029-06",
      "enrollment": 0,
      "sponsor": "BioNTech SE"
    },
    {
      "nct_id": "NCT05968326",
      "title": "A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC",
      "status": "RECRUITING",
      "phase": "PHASE2",
      "condition": "Adenocarcinoma, Pancreatic Ductal",
      "start_date": "2023-10-18",
      "completion_date": "2031-01-01",
      "enrollment": 0,
      "sponsor": "Genentech, Inc."
    },
    {
      "nct_id": "NCT04523571",
      "title": "Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "SARS-CoV-2",
      "start_date": "2020-07-28",
      "completion_date": "2021-08-10",
      "enrollment": 0,
      "sponsor": "BioNTech SE"
    },
    {
      "nct_id": "NCT07365995",
      "title": "A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer",
      "status": "NOT_YET_RECRUITING",
      "phase": "PHASE3",
      "condition": "Metastatic Castration-resistant Prostate Cancer",
      "start_date": "2026-03",
      "completion_date": "2031-02",
      "enrollment": 0,
      "sponsor": "BioNTech SE"
    },
    {
      "nct_id": "NCT05541861",
      "title": "Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "SARS-CoV-2 Infection, COVID-19",
      "start_date": "2022-11-08",
      "completion_date": "2024-11-22",
      "enrollment": 0,
      "sponsor": "BioNTech SE"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "PHASE2": 15,
      "PHASE1": 15,
      "PHASE3": 5,
      "PHASE2, PHASE3": 5,
      "PHASE1, PHASE2": 8,
      "PHASE4": 1,
      "": 1
    },
    "by_status": {
      "COMPLETED": 22,
      "WITHDRAWN": 3,
      "TERMINATED": 6,
      "RECRUITING": 12,
      "NOT_YET_RECRUITING": 3,
      "ACTIVE_NOT_RECRUITING": 4
    },
    "active_trials": 16,
    "completed_trials": 22,
    "conditions": [
      "Adenocarcinoma, Pancreatic Ductal",
      "Advanced Endometrial Cancer",
      "Advanced Lung Cancer",
      "Advanced Melanoma",
      "Advanced Non-Small Cell Lung Cancer",
      "Advanced Solid Tumor",
      "Bacterial Vaginosis",
      "COVID-19",
      "COVID-19, SARS-COV-2 Infection",
      "COVID-19, SARS-CoV-2 Infection",
      "Colorectal Cancer Stage II, Colorectal Cancer Stage III",
      "Covid-19, Protection Against COVID-19",
      "Influenza, COVID-19 (Coronavirus Disease 2019)",
      "Influenza, Human, COVID-19",
      "Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers",
      "Lymphocytic Leukemia",
      "Malignant Solid Tumor",
      "Melanoma",
      "Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma",
      "Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers",
      "Metastatic Castration-resistant Prostate Cancer",
      "Metastatic Colorectal Cancer",
      "Non-small Cell Lung Cancer",
      "Pancreatic Cancer",
      "Pancreatic Carcinoma, Tumors That Express CA 19-9",
      "Pancreatic Carcinoma, Tumors That Express CA19-9",
      "Recurrent Glioblastoma",
      "SARS-CoV-2",
      "SARS-CoV-2 Infection, COVID-19",
      "SARS-CoV-2 Infection, COVID-19, Maternal Immunization",
      "SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)",
      "SARS-CoV-2 Infection, COVID19",
      "Solid Tumor",
      "Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Pancreatic Cancer, Biliary Tract Cancer, Cholangiocarcinoma, Metastatic Cancer",
      "Testicular Germ Cell Tumor, Extragonadal Germ Cell Tumor",
      "Tuberculosis",
      "Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma",
      "Untreated, Unresectable, or Metastatic Colorectal Cancer",
      "Urinary Bladder Cancer, Bladder Tumors, Transitional Cell Carcinoma of the Bladder, Malignant Melanoma, Melanoma, Skin Cancer, Carcinoma, Non-Small-Cell Lung, Lung Cancer"
    ],
    "lead_stage": "commercial"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:17:13.849786",
    "search_query": "BioNTech SE",
    "url": "https://clinicaltrials.gov/search?term=BioNTech+SE"
  }
}